Gilead taps X-Chem’s DNA-encoded libraries for drug discovery

Gilead Sign
X-Chem will screen its DNA-encoded libraries to discover novel antivirals for Gilead.

Gilead Sciences has teamed up with privately held X-Chem, which will screen its DNA-encoded libraries containing over 120 billion small molecules, in the hope of finding new drugs in antiviral and other therapeutic areas.

X-Chem will receive an undisclosed upfront payment, and Gilead has the option to license drug leads for further development if it finds them to be promising. X-Chem is eligible for licensing fees and future milestone payments.

Compounds in X-Chem’s libraries are generated by iterative combinatorial synthesis with unique DNA tags attached to each one of them. When screened against a target of interest, promising molecules that binds to the target are picked out, and their structure information can be obtained based on synthetic history encoded in their unique DNA sequence. Chemicals synthesized through such technology can tackle some difficult targets such as PPI, ubiquitin ligase, epigenetic and antibacterial targets.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: Astellas pens pact to discover drugs in X-Chem’s library

The Gilead deal represents growing interests in DNA-encoded platform and X-Chem’s service in particular. Not long after X-chem’s foundation in 2009, PPD made a strategic move and acquired a controlling share in the Waltham, Massachusetts-based company, and upon expiration of that partnership in 2014, decided to exercise its option to buy it in full. Although X-Chem later spun out of PPD in 2016 based on a new strategic direction to pursue its biotech focus, it has already built a reputation in the industry.

Bayer, which again expanded its multitarget drug discovery collaboration with X-Chem in October, has previously licensed two programs from X-Chem, one against an epigenetic target and one in cardiovascular. On Oct. 31, X-Chem joined a research consortium picked to receive a research grant from the Department of Defense to discover new drugs against tuberculosis. It has also signed deals with U.S. and European companies Roche, AstraZeneca, Pfizer, Janssen, Sanofi, Alexion and Vertex, and with Astellas, Ono and Otsuka’s Taiho in Japan.

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.